{
  "id": 14347639,
  "title": "AbbVie's Subcutaneous Skyrizi Shows Endoscopic Benefits In Crohn's Diseases",
  "url": "https://urgent.news/2026/10/14/abbvies-subcutaneous-skyrizi-shows-endoscopic-benefits-in-crohns",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-14T01:35:50.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/abbvies-subcutaneous-skyrizi-shows-endoscopic-benefits-crohns-diseases"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Tuesday, AbbVie reported new Phase 3 AFFIRM data showcasing endoscopic outcomes with subcutaneous Skyrizi in adults with moderately to severely active Crohn's disease.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}